Biorithm Secures $3.5 Million in Series A Funding to Revolutionize Maternity Care with Precision Medicine Technology

Biorithm, a pioneering medical technology company spun off from Nanyang Technological University Singapore (NTU), has successfully raised $3,500,000 in its latest funding round. This significant investment marks a pivotal moment in the company's mission to redefine maternity care by leveraging predictive and precision medicine to combat preventable pregnancy complications and stillbirth. With the insights gleaned from leading doctors and engineers, Biorithm has developed state-of-the-art analytic software and medical-grade wearables that monitor a vast array of pregnancy data with unparalleled accuracy. This innovative approach empowers healthcare providers and expectant mothers alike, offering real-time insights to navigate the complexities of pregnancy and enhance outcomes. The funds raised will be strategically deployed to further enhance Biorithm's proprietary technology, expand its team of experts, and scale up its operations to serve a broader demographic. As Biorithm continues to forge new frontiers in women's health, the objective of this funding is to refine its product offerings and accelerate the implementation of its life-saving solutions globally. With this infusion of capital, Biorithm is not only positioning itself at the forefront of maternity care but is also committed to making strides toward a future where preventable pregnancy-related issues are a thing of the past. The company remains steadfast in its vision and is prepared to make a tangible difference in the lives of mothers and children everywhere, redefining standards of care one innovation at a time.